company background image
RDGL logo

Vivos OTCPK:RDGL Stock Report

Last Price

US$0.071

Market Cap

US$27.7m

7D

1.6%

1Y

12.7%

Updated

27 Mar, 2024

Data

Company Financials

RDGL Stock Overview

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally.

RDGL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vivos Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivos
Historical stock prices
Current Share PriceUS$0.071
52 Week HighUS$0.12
52 Week LowUS$0.041
Beta1.49
1 Month Change33.01%
3 Month Change-4.82%
1 Year Change12.70%
3 Year Change-30.22%
5 Year Change170.91%
Change since IPO-99.98%

Recent News & Updates

Recent updates

Shareholder Returns

RDGLUS Medical EquipmentUS Market
7D1.6%2.2%0.4%
1Y12.7%13.3%28.8%

Return vs Industry: RDGL matched the US Medical Equipment industry which returned 12% over the past year.

Return vs Market: RDGL underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is RDGL's price volatile compared to industry and market?
RDGL volatility
RDGL Average Weekly Movement11.3%
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: RDGL's share price has been volatile over the past 3 months.

Volatility Over Time: RDGL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19941Mike Korenkohttps://www.radiogel.com

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017.

Vivos Inc. Fundamentals Summary

How do Vivos's earnings and revenue compare to its market cap?
RDGL fundamental statistics
Market capUS$27.68m
Earnings (TTM)-US$2.89m
Revenue (TTM)US$19.50k

1,420x

P/S Ratio

-9.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RDGL income statement (TTM)
RevenueUS$19.50k
Cost of RevenueUS$25.54k
Gross Profit-US$6.04k
Other ExpensesUS$2.89m
Earnings-US$2.89m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0074
Gross Margin-30.95%
Net Profit Margin-14,844.89%
Debt/Equity Ratio0%

How did RDGL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.